228 related articles for article (PubMed ID: 17389606)
21. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.
Hundhausen C; Schulte A; Schulz B; Andrzejewski MG; Schwarz N; von Hundelshausen P; Winter U; Paliga K; Reiss K; Saftig P; Weber C; Ludwig A
J Immunol; 2007 Jun; 178(12):8064-72. PubMed ID: 17548644
[TBL] [Abstract][Full Text] [Related]
22. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
23. T-cell immunoglobulin and mucin domain 2 (TIM-2) is a target of ADAM10-mediated ectodomain shedding.
Dewitz C; Möller-Hackbarth K; Schweigert O; Reiss K; Chalaris A; Scheller J; Rose-John S
FEBS J; 2014 Jan; 281(1):157-74. PubMed ID: 24164679
[TBL] [Abstract][Full Text] [Related]
24. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
25. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
26. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
27. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
[TBL] [Abstract][Full Text] [Related]
28. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases.
Zhang L; Bukulin M; Kojro E; Roth A; Metz VV; Fahrenholz F; Nawroth PP; Bierhaus A; Postina R
J Biol Chem; 2008 Dec; 283(51):35507-16. PubMed ID: 18952609
[TBL] [Abstract][Full Text] [Related]
29. Human P2X7 receptor activation induces the rapid shedding of CXCL16.
Pupovac A; Foster CM; Sluyter R
Biochem Biophys Res Commun; 2013 Mar; 432(4):626-31. PubMed ID: 23428418
[TBL] [Abstract][Full Text] [Related]
30. Induction of RAGE shedding by activation of G protein-coupled receptors.
Metz VV; Kojro E; Rat D; Postina R
PLoS One; 2012; 7(7):e41823. PubMed ID: 22860017
[TBL] [Abstract][Full Text] [Related]
31. The cytoplasmic domain of a disintegrin and metalloproteinase 10 (ADAM10) regulates its constitutive activity but is dispensable for stimulated ADAM10-dependent shedding.
Maretzky T; Evers A; Le Gall S; Alabi RO; Speck N; Reiss K; Blobel CP
J Biol Chem; 2015 Mar; 290(12):7416-25. PubMed ID: 25605720
[TBL] [Abstract][Full Text] [Related]
32. Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum.
Budagian V; Bulanova E; Orinska Z; Duitman E; Brandt K; Ludwig A; Hartmann D; Lemke G; Saftig P; Bulfone-Paus S
Mol Cell Biol; 2005 Nov; 25(21):9324-39. PubMed ID: 16227584
[TBL] [Abstract][Full Text] [Related]
33. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
34. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
Raucci A; Cugusi S; Antonelli A; Barabino SM; Monti L; Bierhaus A; Reiss K; Saftig P; Bianchi ME
FASEB J; 2008 Oct; 22(10):3716-27. PubMed ID: 18603587
[TBL] [Abstract][Full Text] [Related]
35. Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling.
Londino JD; Gulick D; Isenberg JS; Mallampalli RK
J Biol Chem; 2015 Dec; 290(52):31113-25. PubMed ID: 26534964
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.
Schelter F; Grandl M; Seubert B; Schaten S; Hauser S; Gerg M; Boccaccio C; Comoglio P; Krüger A
Clin Exp Metastasis; 2011 Dec; 28(8):793-802. PubMed ID: 21789719
[TBL] [Abstract][Full Text] [Related]
37. Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress.
Clement AB; Hanstein R; Schröder A; Nagel H; Endres K; Fahrenholz F; Behl C
Neuroscience; 2008 Mar; 152(2):459-68. PubMed ID: 18276079
[TBL] [Abstract][Full Text] [Related]
38. Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression.
Twito T; Chen Z; Khatri I; Wong K; Spaner D; Gorczynski R
Leuk Res; 2013 Jul; 37(7):816-21. PubMed ID: 23643150
[TBL] [Abstract][Full Text] [Related]
39. Metalloprotease inhibitor profiles of human ADAM8 in vitro and in cell-based assays.
Schlomann U; Dorzweiler K; Nuti E; Tuccinardi T; Rossello A; Bartsch JW
Biol Chem; 2019 May; 400(6):801-810. PubMed ID: 30738011
[TBL] [Abstract][Full Text] [Related]
40. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.
Parkin E; Harris B
J Neurochem; 2009 Mar; 108(6):1464-79. PubMed ID: 19183255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
